NCT02603575

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.

Conditions

• Pneumocystis Pneumonia

Interventions

Type	Name	Description
DRUG	caspofungin	70mg ivdrip the first day, then 50mg ivdrip qd
DRUG	corticosteroids	40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
DRUG	Sulfanilamides	1.92g q8h

Timeline

• Start date: 2015-11-01
• Primary completion: 2020-12-01
• First posted: 2015-11-13
• Last updated: 2020-03-13

Locations

1 site across 1 country: China